×
-0.000482791916683862 -0.000827643285743876 -0.00220704876198354 -0.00200013794054757 -0.00338644044416866 -0.010966273536106 -0.0189668252982964 -0.0188978550244845
Stockreport

U.S. appeals court invalidates J&J patent on Remicade [Reuters]

JOHNSON & JOHNSON (JNJ)  More Company Research Source: Reuters
Last johnson & johnson earnings: 4/17 06:40 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF U.S. appeals court invalidates J&J patent on Remicade Jan 23 (Reuters) - A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug. The U.S. Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a U.S. administrative court that a J&J patent covering the active ingredient in Remicade was invalid because it was based on an obvious concept. (Reporting by Jan Wolfe) [Read more]

IMPACT SNAPSHOT EVENT TIME: JNJ
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
JNJ alerts
from News Quantified